5-HT1B/1D激动剂利扎曲普坦综述：近期研究进展及对未来的启示。
A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future.
作者信息
Mannix Lisa K
机构信息
Headache Associates and ClinExcel Research 7908 Cincinnati-Dayton Road Suite J, West Chester, OH 45069, USA.
出版信息
Expert Opin Pharmacother. 2008 Apr;9(6):1001-11. doi: 10.1517/14656566.9.6.1001.
BACKGROUND
Among the 5-HT(1B/1D) agonists or 'triptans,' which are considered first-line therapy for acute migraine, rizatriptan has emerged as one of the most efficacious.
OBJECTIVE
Several comprehensive reviews of rizatriptan are available in the literature; the aim of this paper is to review the most current research with rizatriptan.
METHODS
The scope of the review addresses current topics of clinical interest, including studies of time to pain relief, effect of early administration, use in combination with other drugs, and tolerability updates, as well as trials of rizatriptan in certain subpopulations such as patients with menstrual migraine, patients with motion sickness and pediatric patients.
CONCLUSION
In the context of these newly available data, the potential for expansion of the role of rizatriptan in the clinic is evaluated.
背景
在被视为急性偏头痛一线治疗药物的5-羟色胺（1B/1D）激动剂或“曲坦类药物”中，利扎曲普坦已成为最有效的药物之一。
目的
文献中有几篇关于利扎曲普坦的综合综述；本文旨在回顾利扎曲普坦的最新研究。
方法
综述范围涉及当前临床关注的主题，包括疼痛缓解时间的研究、早期给药的效果、与其他药物联合使用、耐受性更新，以及利扎曲普坦在某些亚组患者中的试验，如月经性偏头痛患者、晕动病患者和儿科患者。
结论
在这些新获得的数据背景下，评估了利扎曲普坦在临床中作用扩大的潜力。
Zotero 插件